0.5 ML Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe [Ixiaro]

What the CMS Formulary Data Shows for 0.5 ML Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe [Ixiaro]

Per the CMS 2026 Part D formulary file, 0.5 ML Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe [Ixiaro] (RxNorm concept RXCUI 1300783, generic name 0.5) appears on 328 distinct formulary files spanning 5,052 Medicare Part D plan offerings - 100% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 6, with a cross-plan average of Tier 2.2.

Real-world access to 0.5 ML Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe [Ixiaro] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 1.5% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 888 Part D beneficiaries filled 0.5 ML Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe [Ixiaro] in 2023, with total plan-and-beneficiary spending of $485,593 and an average per-beneficiary annual cost of $546.84. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 0.5 ML Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe [Ixiaro] today.